Is the active ingredient.
Treatment of adults with type 2 diabetes mellitus to improve glycemic control, in combination with other glucoselowering medications or as monotherapy.
Reduction of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
Reduction of hospitalization for heart failure in adults with type 2 diabetes and heart failure or at high risk of developing heart failure.
Empasug 25 Tab (Empagliflozin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works in the kidneys by blocking the reabsorption of glucose into the bloodstream, increasing glucose excretion in the urine. This leads to lower blood glucose levels.
Store at room temperature (20°C to 25°C). Protect from moisture and heat. Keep out of reach of children.
Dosage varies depending on individual needs and other medications. Always follow your doctor's prescription.
Usually taken once daily, orally, with or without food.
Dehydration
Urinary tract infections
Genital yeast infections
Increased urination
Low blood pressure (hypotension)
Ketoacidosis (rare but serious)
Hyperkalemia (high potassium levels)
Alcohol consumption may increase the risk of hypoglycemia. Consult your doctor regarding safe alcohol intake.
May cause dizziness or lightheadedness. Avoid driving or operating machinery if affected.
Not recommended during pregnancy or breastfeeding. Consult your doctor.
Not approved for use in children.
Use with caution in patients with kidney impairment. Dosage adjustments may be needed.
Use with caution in patients with liver impairment. Dosage adjustments may be needed.
Please consult your doctor or pharmacist for specific product information and prescribing details.
Refer to the official drug monograph for detailed information.
